Dubermatinib Uses, Dosage, Side Effects and more
Dubermatinib is under investigation in clinical trial NCT03572634 (Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL).
| Trade Name | Dubermatinib |
| Generic | Dubermatinib |
| Dubermatinib Other Names | Dubermatinib |
| Type | |
| Formula | C24H30ClN7O2S |
| Weight | Average: 516.06 Monoisotopic: 515.1870221 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
